Douglas Lane & Associates LLC Purchases 14,750 Shares of Johnson & Johnson $JNJ

Douglas Lane & Associates LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 2.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 632,425 shares of the company’s stock after acquiring an additional 14,750 shares during the quarter. Johnson & Johnson comprises about 1.4% of Douglas Lane & Associates LLC’s holdings, making the stock its 17th biggest holding. Douglas Lane & Associates LLC’s holdings in Johnson & Johnson were worth $96,603,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Lantz Financial LLC boosted its position in shares of Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock valued at $1,986,000 after acquiring an additional 377 shares during the period. Apexium Financial LP boosted its position in shares of Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after acquiring an additional 2,310 shares during the period. Joel Isaacson & Co. LLC boosted its position in shares of Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after acquiring an additional 2,526 shares during the period. State of Wyoming boosted its position in shares of Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company’s stock valued at $1,487,000 after acquiring an additional 10,279 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after acquiring an additional 4,816 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.2%

JNJ stock opened at $178.10 on Friday. The company has a market capitalization of $428.93 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The company’s 50 day moving average price is $170.81 and its two-hundred day moving average price is $161.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent analyst reports. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Guggenheim reaffirmed a “neutral” rating and issued a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.